577 related articles for article (PubMed ID: 8058730)
1. Immunotherapy with anti-CD3 monoclonal antibodies and recombinant interleukin 2: stimulation of molecular programs of cytotoxic killer cells and induction of tumor regression.
Nakajima F; Khanna A; Xu G; Lagman M; Haschemeyer R; Mouradian J; Wang JC; Stenzel KH; Rubin AL; Suthanthiran M
Proc Natl Acad Sci U S A; 1994 Aug; 91(17):7889-93. PubMed ID: 8058730
[TBL] [Abstract][Full Text] [Related]
2. Immunostimulatory therapy with anti-CD3 monoclonal antibodies and recombinant interleukin-2: heightened in vivo expression of mRNA encoding cytotoxic attack molecules and immunoregulatory cytokines and regression of murine renal cell carcinoma.
Asano T; Khanna A; Lagman M; Li B; Suthanthiran M
J Urol; 1997 Jun; 157(6):2396-401. PubMed ID: 9146677
[TBL] [Abstract][Full Text] [Related]
3. Generation propagation, and targeting of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. An efficient strategy for adoptive tumor immunotherapy.
Nishimura T; Nakamura Y; Takeuchi Y; Tokuda Y; Iwasawa M; Kawasaki A; Okumura K; Habu S
J Immunol; 1992 Jan; 148(1):285-91. PubMed ID: 1345787
[TBL] [Abstract][Full Text] [Related]
4. Successful combination immunotherapy for the generation in vivo of antitumor activity with anti-CD3, interleukin 2, and tumor necrosis factor alpha.
Yang SC; Fry KD; Grimm EA; Roth JA
Arch Surg; 1990 Feb; 125(2):220-5. PubMed ID: 2137327
[TBL] [Abstract][Full Text] [Related]
5. Increased generation of autologous tumor-reactive lymphocytes by anti-CD3 monoclonal antibody and prothymosin alpha.
Baxevanis CN; Spanakos G; Voutsas IF; Gritzapis AD; Tsitsilonis OE; Mamalaki A; Papamichail M
Cancer Immunol Immunother; 1999; 48(2-3):71-84. PubMed ID: 10414460
[TBL] [Abstract][Full Text] [Related]
6. Cellular and molecular mechanisms of activation of MHC nonrestricted cytotoxic cells by IL-12.
Cesano A; Visonneau S; Clark SC; Santoli D
J Immunol; 1993 Sep; 151(6):2943-57. PubMed ID: 8104216
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of superior anti-tumor cytotoxic response of interleukin 15-induced lymphokine-activated killer cells.
Ozdemir O; Ravindranath Y; Savaşan S
J Immunother; 2005; 28(1):44-52. PubMed ID: 15614044
[TBL] [Abstract][Full Text] [Related]
8. Effect of interleukin-1 alpha on the in vitro activation of tumor-draining lymph node cells for adoptive immunotherapy.
Hammel JM; Tuck MK; Hain JM; Chang AE; Sondak VK
J Immunother Emphasis Tumor Immunol; 1994 Jul; 16(1):1-12. PubMed ID: 8081555
[TBL] [Abstract][Full Text] [Related]
9. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
Mulé JJ; Yang J; Shu S; Rosenberg SA
J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD3 + IL-2-stimulated murine killer cells. In vitro generation and in vivo antitumor activity.
Anderson PM; Blazar BR; Bach FH; Ochoa AC
J Immunol; 1989 Feb; 142(4):1383-94. PubMed ID: 2521662
[TBL] [Abstract][Full Text] [Related]
11. IL-4 regulation of perforin gene expression and BLT-esterase production in alpha CD3-induced activated killer cells.
Ting CC; Liang SM; Wang J; Chen YY; Hargrove M; Xu N
Biotechnol Ther; 1994-1995; 5(3-4):99-115. PubMed ID: 8608327
[TBL] [Abstract][Full Text] [Related]
12. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.
Yoshizawa H; Chang AE; Shu S
J Immunol; 1991 Jul; 147(2):729-37. PubMed ID: 1830072
[TBL] [Abstract][Full Text] [Related]
13. Antitumor reactivity of anti-CD3/anti-CD28 bead-activated lymphoid cells: implications for cell therapy in a murine model.
Ito F; Carr A; Svensson H; Yu J; Chang AE; Li Q
J Immunother; 2003; 26(3):222-33. PubMed ID: 12806276
[TBL] [Abstract][Full Text] [Related]
14. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
Lafreniere R; Rosenberg SA
J Immunol; 1985 Dec; 135(6):4273-80. PubMed ID: 3877766
[TBL] [Abstract][Full Text] [Related]
15. Activation of human T cells obtained pre- and post-interleukin-2 (IL-2) therapy by anti-CD3 monoclonal antibody plus IL-2: implications for combined in vivo treatment.
Weil-Hillman G; Schell K; Segal DM; Hank JA; Sosman JA; Sondel PM
J Immunother (1991); 1991 Aug; 10(4):267-77. PubMed ID: 1834166
[TBL] [Abstract][Full Text] [Related]
16. Anti-CD3-activated killer T cells: Interleukin-6 modulates the induction of major histocompatibility complex-unrestricted cytotoxicity and the expression of genes coding for cytotoxic effector molecules.
Greene AL; Makrigiannis AP; Fitzpatrick L; Hoskin DW
J Interferon Cytokine Res; 1997 Dec; 17(12):727-37. PubMed ID: 9452360
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of CTL induction by rapamycin: IL-2 rescues granzyme B and perforin expression but only partially restores cytotoxic activity.
Makrigiannis AP; Hoskin DW
J Immunol; 1997 Nov; 159(10):4700-7. PubMed ID: 9366393
[TBL] [Abstract][Full Text] [Related]
18. Phenotype and cytolytic activity of mouse tumor-bearer splenocytes and tumor-infiltrating lymphocytes from K-1735 melanoma metastases following anti-CD3, interleukin-2, and tumor necrosis factor-alpha combination immunotherapy.
Yang SC; Fry KD; Grimm EA; Roth JA
J Immunother (1991); 1991 Oct; 10(5):326-35. PubMed ID: 1790140
[TBL] [Abstract][Full Text] [Related]
19. Interleukin 2 induction of pore-forming protein gene expression in human peripheral blood CD8+ T cells.
Smyth MJ; Ortaldo JR; Shinkai Y; Yagita H; Nakata M; Okumura K; Young HA
J Exp Med; 1990 Apr; 171(4):1269-81. PubMed ID: 1691263
[TBL] [Abstract][Full Text] [Related]
20. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
Papa MZ; Mulé JJ; Rosenberg SA
Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
